Alphamab OncologyHKEX: 9966

Next Day Disclosure Return

Oct 14, 2026 at 6:43 AM EDT · Issued by Alphamab Oncology via HKEXnews

Filed with HKEX · Stock code 9966 · Oct 14, 2026 at 6:43 AM EDT · 5 pages · English

On 6ix: 6ix.com/news/next-day-disclosure-return-867

Alphamab Oncology on 6ix

Earlier from Alphamab Oncology

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 5
2026 Interim reportSep 24
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast CancerApr 22
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral PresentationApr 22
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary EndpointApr 1

Later from Alphamab Oncology

Discloseable transaction - exercise of warrant to subscribe for preferred stock of pathos AI, inc.Oct 23

All Alphamab Oncology news releases

Follow Alphamab Oncology into a list and get an email when it puts out news.

Follow Alphamab Oncology